These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 30259518)
1. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. Chouliaras K; Newman NA; Shukla M; Swett KR; Levine EA; Sham J; Mann GN; Shen P J Surg Oncol; 2018 Sep; 118(3):416-421. PubMed ID: 30259518 [TBL] [Abstract][Full Text] [Related]
2. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors. Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455 [TBL] [Abstract][Full Text] [Related]
3. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889 [TBL] [Abstract][Full Text] [Related]
4. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study. Kim J; Hong SS; Kim SH; Hwang HK; Kang CM World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Recurrence Between Pancreatic and Duodenal Neuroendocrine Neoplasms After Curative Resection: A Single-Institution Analysis. Masui T; Sato A; Nakano K; Uchida Y; Yogo A; Anazawa T; Nagai K; Kawaguchi Y; Takaori K; Uemoto S Ann Surg Oncol; 2018 Feb; 25(2):528-534. PubMed ID: 29164413 [TBL] [Abstract][Full Text] [Related]
6. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors. Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489 [TBL] [Abstract][Full Text] [Related]
7. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468 [TBL] [Abstract][Full Text] [Related]
8. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395 [TBL] [Abstract][Full Text] [Related]
9. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors. Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734 [TBL] [Abstract][Full Text] [Related]
11. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter? Sallinen V; Haglund C; Seppänen H Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847 [TBL] [Abstract][Full Text] [Related]
13. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Teh SH; Deveney C; Sheppard BC Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366 [TBL] [Abstract][Full Text] [Related]
14. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116 [TBL] [Abstract][Full Text] [Related]
15. A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. Gaitanidis A; Patel D; Nilubol N; Tirosh A; Kebebew E J Clin Endocrinol Metab; 2018 Jan; 103(1):187-195. PubMed ID: 29069375 [TBL] [Abstract][Full Text] [Related]
16. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141 [TBL] [Abstract][Full Text] [Related]
17. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972 [TBL] [Abstract][Full Text] [Related]
18. Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survival. Addeo P; d'Alessandro A; Averous G; Imperiale A; Faitot F; Goichot B; Bachellier P HPB (Oxford); 2019 Jun; 21(6):653-661. PubMed ID: 30522946 [TBL] [Abstract][Full Text] [Related]
19. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor. Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173 [TBL] [Abstract][Full Text] [Related]